Galmed Pharmaceuticals
GLMD
12 hedge funds and large institutions have $143K invested in Galmed Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
273% more capital invested
Capital invested by funds: $38.3K → $143K (+$104K)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
20% more funds holding
Funds holding: 10 → 12 (+2)
2.59% more ownership
Funds ownership: 0.37% → 2.97% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
+$86K |
| 2 |
Morgan Stanley
New York
|
+$42.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$4.92K |
| 4 |
DWM
Dogwood Wealth Management
Lenexa,
Kansas
|
+$3 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$386 |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
1
Schonfeld Strategic Advisors
New York
| $81K | +$86K | +25,400 | New |
|
|
2
Morgan Stanley
New York
| $40K | +$42.1K | +12,426 | +11,948% |
|
|
3
UBS Group
Zurich,
Switzerland
| $21.4K | +$4.92K | +1,454 | +28% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $188 | -$386 | -114 | -66% |
|
5
Wells Fargo
San Francisco,
California
| $57 | – | – | – |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| $51 | +$54 | +16 | New |
|
|
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $45 | – | – | – |
|
8
Osaic Holdings
Scottsdale,
Arizona
| $15 | – | – | – |
|
|
AF
9
Allworth Financial
Folsom,
California
| $6 | – | – | – |
|
|
EWP
10
Elevation Wealth Partners
Santa Rosa,
California
| $4 | – | – | – |
|
|
DWM
11
Dogwood Wealth Management
Lenexa,
Kansas
| $3 | +$3 | +1 | New |
|
|
12
BNP Paribas Financial Markets
Paris,
France
| – | -$7 | -1 | Closed |
|
GLMD Hedge Fund Activity: Q4 2024 in Review
12 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q4 2024, worth a combined $143K — up 273% from $38.3K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GLMD positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Schonfeld Strategic Advisors, opening a new position worth an estimated $86K. The largest seller was Tower Research Capital (TRC), cutting an estimated $386.
- 12 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q4 2024, up from 10 in Q3 2024.
- Funds reported $143K of Galmed Pharmaceuticals stock for Q4 2024, up 273% quarter-over-quarter.
- 3 funds opened new Galmed Pharmaceuticals positions in Q4 2024 and 1 closed out, a net change of +2 holders.
- The largest Galmed Pharmaceuticals buyer in Q4 2024 was Schonfeld Strategic Advisors, an estimated $86K added.
- The largest Galmed Pharmaceuticals seller in Q4 2024 was Tower Research Capital (TRC), an estimated $386 sold.
Based on aggregated 13F filings for Q4 2024.